| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
Hexahydrofarnesyl acetone does not have a well-defined specific molecular target. It exhibits antibacterial activity against various bacterial strains and anti-inflammatory activity. The compound's mechanism of action may involve modulation of inflammatory pathways, but detailed target identification studies are limited. It enhances both sticky materials production and cell growth, playing a role in the increase of sticky materials and cell growth.
|
|---|---|
| ln Vitro |
Hexahydrofarnesyl acetone demonstrates antibacterial activity in vitro. It exhibits anti-inflammatory activity and may be used in pain relief studies. The compound enhances both sticky materials production and cell growth. Its activity is typically assessed in antimicrobial susceptibility assays and anti-inflammatory cytokine production assays.
|
| ln Vivo |
In vivo activity of hexahydrofarnesyl acetone has been suggested by its anti-inflammatory and antibacterial properties. The compound's potential for pain relief suggests possible in vivo efficacy in pain models. Further in vivo studies are needed to fully characterize its pharmacokinetic properties, efficacy, and safety profile in animal models.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for hexahydrofarnesyl acetone are not extensively documented. Its antibacterial activity is assessed using standard microbial growth inhibition assays, where the compound's ability to inhibit the growth of bacteria is measured. Anti-inflammatory activity can be evaluated by measuring cytokine production in activated immune cells using ELISA or multiplex assays.
|
| Cell Assay |
In vitro cellular assays for hexahydrofarnesyl acetone involve culturing bacterial cells or immune cells in the presence of varying concentrations of the compound. Antibacterial activity is assessed by measuring inhibition of growth using optical density measurements or colony counting. Anti-inflammatory activity is evaluated by measuring cytokine levels (e.g., IL-6, TNF-α) in stimulated immune cells using ELISA.
|
| Animal Protocol |
In vivo animal experiments for hexahydrofarnesyl acetone are not extensively documented. If used in animal models of inflammation or pain, typical protocols would involve administering the compound to animals and evaluating efficacy by measuring inflammatory markers, pain responses, or clinical outcomes. Further studies are needed to characterize its in vivo activity.
|
| ADME/Pharmacokinetics |
Hexahydrofarnesyl acetone has a molecular weight of 268.48 and a molecular formula of C18H36O. It is a colorless to light yellow liquid with a density of 0.8±0.1 g/cm³, boiling point of 316.8±10.0 °C, and LogP of 7.26. It is soluble in DMSO at 33.33 mg/mL (124.14 mM). Powder should be stored at -20°C for up to 3 years and at 4°C for up to 2 years; solutions at -80°C for 6 months or -20°C for 1 month.
|
| Toxicity/Toxicokinetics |
Toxicological data for hexahydrofarnesyl acetone are limited. As a natural product-derived sesquiterpene, it is generally considered to have low toxicity, but comprehensive toxicological studies have not been reported. The compound is intended for research use only. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Hexahydrofarnesyl acetone is a ketone. It has been reported that 6,10,14-trimethylpentadecan-2-one exists in Listeria guinea, Pinellia ternata, and other organisms with relevant data.
Hexahydrofarnesyl acetone (phytone; 6,10,14-Trimethyl-2-pentadecanone) (CAS#: 502-69-2) has the molecular formula C18H36O and a molecular weight of 268.48. Its IUPAC name is 6,10,14-trimethylpentadecan-2-one. The compound is a sesquiterpene extracted from Impatiens parviflora and is the major component of volatile oil. It has antibacterial and anti-inflammatory activity. Purity is ≥98%. It is for research use only. |
| Molecular Formula |
C18H36O
|
|---|---|
| Molecular Weight |
268.48
|
| Exact Mass |
268.276
|
| CAS # |
502-69-2
|
| PubChem CID |
10408
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
0.8±0.1 g/cm3
|
| Boiling Point |
316.8±10.0 °C at 760 mmHg
|
| Flash Point |
95.1±12.6 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.440
|
| LogP |
7.26
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
19
|
| Complexity |
220
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)CCCC(C)CCCC(C)CCCC(=O)C
|
| InChi Key |
WHWDWIHXSPCOKZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H36O/c1-15(2)9-6-10-16(3)11-7-12-17(4)13-8-14-18(5)19/h15-17H,6-14H2,1-5H3
|
| Chemical Name |
6,10,14-trimethylpentadecan-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 33.33 mg/mL (124.14 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.31 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.31 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.31 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7247 mL | 18.6234 mL | 37.2467 mL | |
| 5 mM | 0.7449 mL | 3.7247 mL | 7.4493 mL | |
| 10 mM | 0.3725 mL | 1.8623 mL | 3.7247 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
